SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-23-000987
Filing Date
2023-05-11
Accepted
2023-05-11 08:15:51
Documents
76
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20230331x10q.htm   iXBRL 10-Q 1348100
2 EX-10.1 tmb-20230331xex10d1.htm EX-10.1 87071
3 EX-10.2 tmb-20230331xex10d2.htm EX-10.2 76932
4 EX-31.1 tmb-20230331xex31d1.htm EX-31.1 15909
5 EX-32.1 tmb-20230331xex32d1.htm EX-32.1 6494
6 GRAPHIC tmb-20230331x10q001.jpg GRAPHIC 54978
  Complete submission text file 0001410578-23-000987.txt   7021006

Data Files

Seq Description Document Type Size
7 EX-101.SCH tmb-20230331.xsd EX-101.SCH 53323
8 EX-101.CAL tmb-20230331_cal.xml EX-101.CAL 59751
9 EX-101.DEF tmb-20230331_def.xml EX-101.DEF 218896
10 EX-101.LAB tmb-20230331_lab.xml EX-101.LAB 473528
11 EX-101.PRE tmb-20230331_pre.xml EX-101.PRE 353159
70 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20230331x10q_htm.xml XML 1148579
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12584 | Film No.: 23908975
SIC: 2834 Pharmaceutical Preparations